Cyclosporine is an immunosuppressant medication used primarily to prevent organ rejection after transplant surgery and to treat severe autoimmune conditions like rheumatoid arthritis and psoriasis. It also comes in an eye drop formulation for chronic dry eye. The drug works by dialing down the immune system’s activity, which makes it valuable in situations where the body’s own defenses are causing harm.
How Cyclosporine Works
Cyclosporine belongs to a class of drugs called calcineurin inhibitors. Your immune system relies on T-cells to identify and attack threats, but in transplant rejection and autoimmune diseases, those same T-cells target healthy tissue. Cyclosporine blocks a key step in T-cell activation: it prevents T-cells from producing a signaling molecule called IL-2, which normally triggers them to multiply and mount an immune response. Without that signal, the T-cells can’t ramp up into a full attack.
Beyond just blocking the alarm signal, cyclosporine also reduces T-cells’ ability to take up glucose and shift into their high-energy “fight mode.” This means the drug doesn’t just silence the message; it cuts off the fuel supply that immune cells need to cause damage. The result is broad, targeted suppression of the immune responses responsible for organ rejection, joint destruction in arthritis, and the rapid skin cell turnover in psoriasis.
Preventing Organ Transplant Rejection
The most critical use of cyclosporine is preventing the body from rejecting a transplanted organ. It is FDA-approved for kidney, liver, and heart transplants. After surgery, the immune system recognizes the new organ as foreign and will try to destroy it unless it’s held in check. Cyclosporine is typically started within hours of the transplant and continued long-term, often for the life of the organ.
In the early weeks after transplant, higher doses are needed because the risk of rejection is greatest. Blood levels of the drug are monitored closely during this period, with target trough concentrations generally kept between 150 and 400 ng/mL for the first two months. After that initial window, the target range drops to 75 to 300 ng/mL as the body begins to tolerate the new organ and the risk of rejection decreases. Doses are gradually tapered, typically reduced by about 5% per week until reaching a lower maintenance level.
This monitoring matters because cyclosporine has a narrow therapeutic window. Too little and rejection becomes likely; too much and the side effects, particularly kidney damage, become a real concern. Blood draws to check drug levels are a routine part of life for transplant patients, especially in the first year.
Severe Rheumatoid Arthritis
Cyclosporine is approved for severe, active rheumatoid arthritis that hasn’t responded adequately to methotrexate, the most commonly used first-line treatment. It can be prescribed alone or added on top of methotrexate for patients who need more disease control.
In rheumatoid arthritis, the immune system attacks the lining of the joints, causing pain, swelling, and progressive damage. By suppressing the T-cell response driving that inflammation, cyclosporine can slow joint destruction and reduce symptoms. It’s not typically a first choice for arthritis because of its side effect profile, but for patients with aggressive disease who haven’t found relief from standard treatments, it offers a meaningful option.
Severe Plaque Psoriasis
For psoriasis, cyclosporine is reserved for severe cases: widespread, disabling plaque psoriasis in adults who have already tried and failed at least one other systemic treatment, such as light therapy, retinoids, or methotrexate. It works quickly compared to many psoriasis treatments, which makes it useful for getting a severe flare under control.
The preferred approach is short-term use, typically 12 to 16 weeks. This controlled burst can clear or significantly reduce plaques, after which patients transition to a different long-term maintenance therapy. In cases where nothing else controls the disease, cyclosporine may be continued for a year or longer, though this increases the risk of kidney problems and high blood pressure, so ongoing monitoring is essential. The short-course strategy reflects a broader principle with this drug: use it powerfully when you need it, then step down to something gentler when possible.
Chronic Dry Eye Disease
Cyclosporine is also available as an eye drop, most widely known under the brand name Restasis. The ophthalmic formulation contains a very low concentration of cyclosporine (0.05%) and is used to treat chronic dry eye caused by inflammation on the surface of the eye. The standard dosing is one drop in each eye twice a day, about 12 hours apart.
Dry eye might sound minor compared to organ rejection, but chronic cases involve real inflammation that damages the tear-producing glands over time. The cyclosporine in these drops works locally, calming the immune activity on the eye’s surface so your eyes can produce more of their own natural tears. It’s not a quick fix. Most people need several weeks to a few months of consistent use before noticing significant improvement, which is why many patients give up on it too early. Unlike artificial tears that simply add moisture temporarily, cyclosporine eye drops address the underlying inflammation driving the dryness.
Other Conditions Treated With Cyclosporine
Beyond its FDA-approved uses, cyclosporine is prescribed for a range of other immune-mediated conditions. Dermatologists use it for severe atopic dermatitis (eczema) when topical treatments aren’t enough, particularly in countries outside the United States where it carries formal approval for that indication. Gastroenterologists sometimes turn to it for severe ulcerative colitis flares that don’t respond to steroids, where it can serve as a bridge to avoid emergency surgery. It also sees use in certain kidney diseases, including some forms of nephrotic syndrome where the immune system damages the kidney’s filtering units.
These uses reflect cyclosporine’s broad immunosuppressive reach. Any condition where overactive T-cells are a central driver of tissue damage is at least a theoretical candidate, though the drug’s side effects mean it’s generally reserved for situations where safer options have failed.
Side Effects and Monitoring
Cyclosporine’s biggest concern is kidney toxicity. The drug can reduce blood flow to the kidneys, and over months or years of use, this can lead to permanent damage. Blood pressure often rises as well, so regular monitoring of kidney function and blood pressure is standard for anyone taking systemic cyclosporine. These risks are dose-dependent, which is why doctors use the lowest effective dose and prefer short treatment courses when possible.
Other common side effects include tremor, excessive hair growth, swollen gums, headache, and nausea. Because the drug suppresses the immune system, infections become more likely, and long-term use increases the risk of certain cancers, particularly skin cancers and lymphomas. Transplant patients, who take cyclosporine for years or decades, carry the highest cumulative risk, which is why sun protection and regular skin checks become part of their routine. For shorter-term users treating psoriasis or arthritis, these risks are lower but still worth understanding.
The ophthalmic formulation carries far fewer systemic risks because so little of the drug enters the bloodstream. The most common complaint with the eye drops is a burning or stinging sensation when they’re applied, which tends to improve with continued use.